Hidehito HORINOUCHI· @HHorinouchi · X·· 1 天前评分70
正文 · 机器翻译
🔥Krascendo 1：既往接受过治疗的 KRAS G12C 突变型 NSCLC 中，Divarasib 对比 sotorasib/adagrasib
🆙 @NEJM #ESMO26
☑3期随机对照试验（RCT）；N=338；中位随访时间（mFU）14.3个月
🎯中位PFS（mPFS）9.8 vs 5.7个月（HR 0.58，p<0.001）；中位OS（mOS）17.7 vs 12.0个月（HR 0.56，p<0.001）；ORR 58.4 vs 32.3%
🎙 @FSkoulidis
#LCSM @OncoAlert @Larvol @KRASKickers
https://www.nejm.org/doi/full/10.1056/NEJMoa2605703
142 浏览 · 4 赞 · 3 转发 · 0 回复
会议摘要
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org🆙#ESMO26 Presidential Symposium II: #LCSM 🔥Krascendo 1: Efficacy and Safety of Divarasib (Diva) vs Sotorasib (Soto) or Adagrasib (Ada) in Previously Treated Locally Advanced or Metastatic KRAS G12C-Mutated NSCLC 🎙️ @FSkoulidis 🔢LBA5 🎯Significantly Improved PFS (9.8 vs 5.7mo, HR 0.58; n=338) and OS (17.7 vs 12.0mo, HR 0.56, p=0.0005) 🎯ORR 58.4% vs 32.3% 🎯Discontinuation Due to TRAEs 4.8% vs 11.7% ☑️NCT06497556 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/348 @OncoAlert @Larvol @myESMO @IASLC @KRASKickers在 X 查看被引用的帖子
来源：Hidehito HORINOUCHI · x.com